絞り込み

16602

広告

1279件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

Cost-effectiveness of edoxaban versus dalteparin for the treatment of cancer-associated thrombosis.

Current and Emerging Direct Oral Anticoagulants: State-of-the-Art.

Pulmonary embolism: update on diagnosis and management.

Effectiveness and Safety of Contemporary Oral Anticoagulants Among Asians With Nonvalvular Atrial Fibrillation.

Liquid chromatographic methods for the determination of direct oral anticoagulant drugs in biological samples: A critical review.

Oral anticoagulants in atrial fibrillation with valvular heart disease and bioprosthetic heart valves.

Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus dalteparin for the treatment of cancer associated thrombosis (CAT) in the United States.

Sustained safe and effective anticoagulation using Edoxaban via percutaneous endoscopic gastrostomy.

[Major gastrointestinal hemorrhage during anticoagulant therapy in patients with atrial fibrillation: when should treatment be resumed?]

The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review.

[Dissolution and maintenance of portal vein thrombosis with antithrombin III and edoxaban in liver cirrhosis:a case report].

Reversal of oral anticoagulation in patients with acute intracerebral hemorrhage.

Deep vein thrombosis: update on diagnosis and management.

Evaluation of Direct Oral Anticoagulant Dosing and Monitoring in Two Geriatric Outpatient Clinics.

Real-life Performance of Edoxaban in Elderly Patients With Atrial Fibrillation: a Multicenter Propensity Score-Matched Cohort Study.

All-Cause Mortality and Cardiovascular Outcomes With Non-Vitamin K Oral Anticoagulants Versus Warfarin in Patients With Heart Failure in the Food and Drug Administration Adverse Event Reporting System.

The Impact of Cancer on Major Bleeding and Stroke/Systemic Emboli in Patients Using Direct Oral Anticoagulants:From the Database of a Single-Center Registry.

Prevalence and Characteristics of Venous Thrombosis after Catheter Ablation of Atrial Fibrillation in Patients Receiving Periprocedural Direct Oral Anticoagulants.

Elderly Bleeding Risk of Direct Oral Anticoagulants in Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Cohort Studies.

Responses of prothrombin time and activated partial thromboplastin time to edoxaban in Japanese patients with non-valvular atrial fibrillation: characteristics of representative reagents in Japan (CVI ARO 7).

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
Sort by
※並べ替えは表示に時間がかかります